Monday, August 30, 2021

During the SARS-Cov-2 pandemic, the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying member sites across 17 European countries and collated information on measures to mitigate the impact of the pandemic and ensure trial continuity.
Please check the publication resulting from this work: van Koningsbruggen-Rietschel et al. , Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures., Trials (2021) 22:578,

Access to the article